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In Alzheimer’s disease, indoleamine 2,3-dioxygenase and tryptophan hydroxylase are known to induce an overproduction of
neurotoxic compounds, such as quinolinic acid and 3-hydroxykynurenine from the former, and 5-hydroxytryptophol and 5-
methoxytryptopholfromthelatter.Othercompounds,suchaskynurenicacid,serotonin,andmelatoninareproducedviathesame
pathways. An improved ELISA method identiﬁed circulating antibodies directed against these compounds, linked to proteins, as
previously described for other chronic diseases. This describes how only the A isotype of circulating immunoglobulins recognized
a pattern of conjugated tryptophan metabolites in the sera of Alzheimer patients. These data indirectly conﬁrmed the involvement
of tryptophan derivatives in the pathogenic processes of Alzheimer’s disease. Further studies are required to evaluate the relevance
of these antibody patterns in monitoring this disease.
1.Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder,
resulting in a gradual, irreversible loss of memory and
cognitive functions [1], mainly aﬀecting cholinergic neu-
rons. The severity of AD depends on the dysfunction
of two molecules: Amyloid protein precursor (APP) and
Tau protein. The aggregation of these proteins results in
senile plaque formation and neuroﬁbrillar degeneration.
Pathological mutations have been discovered on the APP
gene, in the region coding for the Beta amyloid peptide
(Aβ), as well as on the presenilin PS1 and PS2 genes. PS1
and PS2 proteins regulate APP catabolism. Despite this new
knowledge, the etiology of AD remains largely unknown.
Common pathogenic disorders reported in AD include:
autoimmunity [2], excitotoxicity, and oxidative and radical
processes [3], all inducing neuron death and the activation
of microglia cells and astrocytes [4].
One mechanistic hypothesis focuses on the tryptophan
molecule, an amino acid essential for cell growth and
metabolism. In the central nervous system, tryptophan
is metabolized via two pivotal biochemical pathways [5],
shown in Figures 1(a) and 1(b).
In the ﬁrst pathway, tryptophan is metabolized by
indoleamine-2, 3-dioxygenase-1 (IDO-1), an enzyme found
in many tissues. IDO-1 catalyses tryptophan to N-
formylkynurenine, an intermediate for several biochemical
compounds. Moreover, IDO-1 is an inducible enzyme,
activated in AD by proinﬂammatory cytokines, such
as interferon-gamma (IFN-γ)[ 6], interleukin-12 (IL-12),
interleukin-18 (IL-18) [7], and the Aβ 1-42 fragment [8].
Tryptophan catabolism abnormalities have been observed
in AD. The tryptophan catabolism [9]a n ds e r i ck y n u r e -
nine/tryptophan ratio [10] increase in AD patients. Neu-
roinﬂammation in the central nervous system (CNS) may be
a major factor in this disease, due to cytotoxic tryptophan
metabolite production by CNS inﬁltrating macrophages and
glial cells [11]. Dementia in AD patients is correlated with
the overproduction of quinolinic acid (Quina) [12, 13],
a metabolite of tryptophan accumulated in neurons and
astrocytes via proinﬂammatory processes [14].
In the second pathway, tryptophan hydroxylase (THO),
a rate-limiting enzyme, generates serotonin (5-HT) and
melatonin (Mel), among other compounds. A loss of
serotoninergic neurons has also been observed [15]. Mel2 International Journal of Alzheimer’s Disease
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Figure 1: (a) The IDO-1 pathway. (b) the THO pathway.
is an important antioxidant, anti-inﬂammatory mediator
[16] that interacts directly with Aβ deposition and hyper-
phosphorylated Tau protein. It plays a role in cholinergic
neuroprotection [17]. THO activity decreases in the aging
brain [18]. However, the THO pathway indirectly produces
neurotoxic metabolites, such as 5-methoxytryptophol (5-
MTol), 5-hydroxytryptophol (5-HTol), and the oxidative
compound 5-hydroxyindole acetic acid (5-HIAA) via an
enzyme cascade. All of these molecules play numerous roles
in AD [19].
The aim of this study was to assay circulating antibodies
directed against tryptophan derivatives conjugated to pro-
teins in order to mimic the pathogenic mechanisms in vivo.
TheantibodytitersinADpatientserawerethuscomparedto
controls. The identiﬁcation of speciﬁc antibodies in AD may
enhances our understanding of some of the immunological
processes involved.
2.MaterialsandMethods
2.1. Patient Sera. The study was conducted in accordance
with Good Clinical Practice guidelines, with the informed
consent of the patients, their caregivers, and the controls, in
application of French and European law and current medical
procedures. In this study, healthy control populations were
matchedbyageand sexwith theADpatients. Serumsamples
from 48 patients (age range: 65–85) were used. There was
no subclassiﬁcation among the AD states associated with
dementia.Twentyserumsampleswereobtainedfromhealthy
controls (age range: 64–82).
AD was diagnosed according to the criteria outlined by
the National Institute of Neurological and Communicative
Disorders and Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA), in the absence of any
clinical or laboratory evidence of a cause other than AD for
dementia [20]. The patients had mild to moderately severe
disease as deﬁned by the Mini-Mental State Examination
(MMSE) [21], with scores of 10 to 26, and screening and
baseline Clinical Dementia Rating (CDR), with scores of 1
o r2[ 22]. None of the patients had AD aggravated by an
additional diagnosis of delusion, delirium, or depression,
and none had a known or suspected history of alcoholism
or drug abuse.
2.2. Conjugate Synthesis. Each tryptophan derivative was
dissolved in 200 μL dimethylsulfoxide (DMSO) (Acros).
Bovine serum albumin (BSA) (ID Bio) was also dis-
solvedin3mL2-morpholino-ethanesulfonicacidmonohyd-
rate (MES) buﬀer 10−1 M (pH 6.3) (Acros). Then, the
tryptophan derivatives were mixed with the BSA solu-
tion and supplemented with 15mg N-hydroxysuccinimide
(Sigma) and 1-(3-dimethylaminopropyl)-3-ethylcarbodi-
imide (Acros) as coupling agents [23]. The conjugates were
synthesized by linking 10mg kynurenine (Kyn) (Sigma), or
3-hydroxykynurenine (3-OHKyn) (Sigma), kynurenic acid
(Kyna) (Acros), Quina (Acros), quinaldic acid (Quinald)
(Acros), 3-hydroxyanthranilic acid (3-OHAnthra) (Aldrich),
anthranilicacid(Anthra)(Acros),xanthurenicacid(Xantha)
(Acros), picolinic acid (Pico) (Acros), or 5-hydroxyindole
acetic acid (5-HIAA) (Sigma), to 20mg BSA. The coupling
reaction took place in darkness, at 37◦C, for 1 hour. TheInternational Journal of Alzheimer’s Disease 3
reaction was stopped by adding 100mg hydroxylamine
(Sigma-Aldrich) per conjugate. The protein conjugates were
dialyzed with 10−1 M NaCl solution for 72 hours and the
bath solution was changed at least four times per day. The
conjugated tryptophan derivative and BSA concentrations
were evaluated by spectrophotometry. The coupling ratio
of each conjugate was calculated from the absorbance
values.
Tryptophan (Sigma), 5-hydroxytryptophan (5-HW)
(Sigma), and 5HT (Sigma) were linked to BSA with glu-
taraldehyde (G), as previously described in [24, 25].
Mel (Sigma), 5-MTol (Sigma), and 5-HTol (Sigma)
conjugates were synthesized as follows: 5mg of each hapten
were shaken in 1mL water/ethanol (vol/vol) and mixed
with 20mg BSA (previously dissolved in 1mL deionized
water) plus 600 μL3 Ma c e t a t eb u ﬀer (Sigma). One mL 2%
formaldehyde solution was added to the mixture and the
reaction was stabilized after 5 minutes at room temperature.
Theconjugatesweredialyzedwitha10−2 Mphosphatebuﬀer
solution (NaH2PO4, 12H2O) and 0.15M NaCl, (pH 7.4), 3
times per day for 72 hours.
2.3. Evaluation of the Molecular Coupling Ratio. The molec-
ular coupling ratio of each conjugate was determined by
measuring the concentration of tryptophan derivative and
BSA at 310–330nm and 280nm, respectively, as previously
d e s c r i b e di n[ 23], taking into account the molar extinction
coeﬃcients after coupling.
2.4. ELISA. ELISA was used to determine the titers of G,
M, or A immunoglobulins (Ig). The protocol has been
extensively described elsewhere [23–25]. Brieﬂy, polystyrene
96-well plates (NUNC) were coated with 200 μLs o l u t i o n
containing10–50μg/mLtryptophan-derivativeconjugatesin
0.05M carbonate buﬀer (pH 9.6). Well plates were incubated
under agitation at 4◦C for 16 hours. Then, 200 μL blocking
buﬀer A (PBS, 2.5 g/L BSA) were applied and samples were
incubated at 37◦C for 1 hour. Well plates were washed
with PBS solution and ﬁlled with 200 μL serum diluted
1:500 in blocking buﬀer A for IDO derivatives and 5-
HIAA or blocking buﬀer B (PBS, 10% glycerol and 2.5
g/L BSA) for the other conjugates. They were incubated at
37◦C for 2 hours. Well plates were washed 3 times with
PBS, 0.05% Tween 20, incubated with peroxidase-labeled
antihuman IgG (Biorad), anti-human IgM (Pierce), or anti-
human IgA (Pierce) antibodies at 37◦Cf o r1h o u r .T h e s e
anti-isotype antibodies were diluted 1: 50,000, 1: 25,000, and
1: 14,000 in blocking buﬀer C (PBS, 0.05% Tween 20, 2.5
g/l BSA), respectively. Plates were then washed three times
with PBS, 0.05% Tween 20, and incubated with the detection
solutionindarknessfor10minutes.Thechromogensolution
consisted of 8% orthophenyldiamine (OPD, Sigma Aldrich)
in a 0.1, M sodium citrate and 0.01, M phosphate buﬀer
(pH5.0),containing0.01%H2O2 (Merck)fortheperoxidase
assay.Thereactionwasstoppedusing50μL2-NHCl(Sigma-
Aldrich). Optical densities (ODs) were measured at 492nm
using a Multiscan spectrophotometer. All assays were carried
out in duplicate.
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Figure 2: Scattergrams represent the OD values for AD patients
(P) and controls (C) for each conjugate (statistically signiﬁcant)
and isotype (statistically signiﬁcant). The ﬁrst lane of OD values
corresponds to C and the second to P. IgA for: (1) 3-OHKyn, (2)
Kyna, (3) Quina, (4) 3-OHAnthra, (5) Anthra, (6) Xantha, (7) Pico,
(8) 5-HT, (9) Mel, (10) 5-HIAA, and (11) 5-MTol.
2.5. Statistical Analysis. The OD of each BSA-coated well
was subtracted from the OD of each well containing
the tryptophan derivative. The Mann and Whitney U-test
was used to compare the AD and healthy sera for each
tryptophan-derivative conjugate. All statistical analyses were
considered signiﬁcant when P ≤ .01. The proportion of
positive sera was calculated as the number of patients with
an OD above the mean control group OD value +2 standard
deviations.
3. Results and Discussion
The presence of circulating antibodies directed against con-
jugated tryptophan metabolites indirectly revealed the over-
production of metabolites associated with hyperactivation of
the IDO-1 in AD, as previously described in [23]. However,
no previous study had shown the presence of circulating
antibodies against THO-pathway-derived metabolites. Some
statistically signiﬁcant results are shown in Figure 2 and
Table 1. IgA responses were observed only for the antibodies
directed against the following IDO-1 pathway metabolites:
3-OHKyn, Kyna, Quina, 3-OHAnthra, Anthra, Xantha, and
Pico. The role of Quina and 3OH-Kyn in neurological
disorders has been previously described in numerous studies
[26]. An accumulation of Quina in astrocytes and neurons
is one of the events associated with depression or dementia
in AD. Quina acts as an agonist of the N-methyl-d-
aspartate (NMDA) receptor and plays a direct role as an
excitotoxic agent [27]. Rahman et al. [28] showed that
Quina was colocalized with the hyperphosphorylated Tau
protein of cortical neurons in AD brains and induced Tau
protein phosphorylation. Decreased concentrations of Kyna,
a Quina antagonist, were found in AD patient sera: Hartai
et al. [29] reported a decrease in Kyna concentrations in
plasma and red-blood cells, while Kyn levels and kynurenine
aminotransferase I and II activity remained unchanged.
However, our results revealed antibodies directed against
conjugated Kyna in the sera. Moreover, Baran et al. [30]
previously observed that a signiﬁcant increase in Kyna pro-
duction in the putamen and caudate nucleus of AD patients4 International Journal of Alzheimer’s Disease
Table 1: Signiﬁcance (P ≤ .01) of OD values (U Mann and Whitney t-test) and percentage of AD positive patients on well plates coated
with tryptophan-derivative conjugates. OD values for each tryptophan-derivative conjugate were subtracted from those on BSA well plates.
Percentages were calculated as follows: number of patients with OD values above mean OD value of controls +2 standard deviations.
Conjugates coated on well plates
Isotype Kyn 3-0HKyn Kyna Quina Quinald 3-OHAnthra Anthra Xantha
G Signiﬁcance 0.0836 0.5746 0.5758 0.8793 0.7513 0.0194 0.1576 0.0635
Percentage 25.4% 10.9% 10.9% 7.2% 16.3% 9.0% 14.7% 20.0%
M Signiﬁcance 0.8275 0.8741 0.9784 0.0000 0.3450 0.2294 0.8172 0.9895
Percentage 29% 9.0% 18.1% 7.2% 32.7% 14.5% 21.8% 21.8%
A Signiﬁcance 0.0015 0.0001 0.0000 0.0027 0.0119 0.0034 0.0026 0.0005
Percentage 38.1% 58.1% 61.8% 65.4% 43.6% 50.9% 54.5% 63.6%
Isotype Pico W 5-HW 5-HT Mel 5-HIAA 5-HTol 5-MTol
G Signiﬁcance 0.0790 0.9042 0.0000 0.0118 0.3873 0.0878 0.4244 0.6936
Percentage 12.7% 24.1% 27.5% 20.6% 20.6% 10.3% 10.3% 6.8%
M Signiﬁcance 0.9737 0.0007 0.0000 0.7928 0.4906 0.4181 0.3696 0.6941
Percentage 23.6% 3.4% 3.4% 10.3% 10.3% 24.1% 6.8% 3.4%
A Signiﬁcance 0.0011 0.0878 0.2836 0.0001 0.0018 0.0001 0.0010 0.0015
Percentage 65.4% 10.3% 13.7% 62% 51.7% 58.6% 41.3% 51.7%
was associated with an elevated kynurenine metabolism.
Xantha production via the IDO-1 pathway is higher in
depressed patients than controls [31] and plays a role in
apoptosis [32], as well as acting as a neuromodulator in the
rat brain [33]. The production of 3-OH anthra, Anthra, and
Pico in AD had not previously been studied in suﬃcient
detail. The IDO-1 pathway is a key regulator of the immune
response. IDO-1 induction and expression tends to limit
the extracellular tryptophan pool necessary for lymphocyte
proliferation [34] and pathogen invasion [35].
As in the case of the IDO-1 pathway, IgA antibodies
werealsofoundagainstsomeTHOpathwaymetabolites,that
is: the neurotransmitter 5-HT, the neuroprotector Mel, and
the neurotoxic metabolites 5-HIAA, and 5-MTol. Mel and
5-MTol production is dependent on the overexpression of
Hydroxyindole-O-metyltransferase,whichmaybeindirectly
responsible for the large increase in circulating antibodies
directed against Mel and 5-MTol, synthesized mainly in
the pineal gland [36]. Their production obeys a circadian
rhythm in healthy persons, which tends to disappear in AD
patients [37].
Burke et al. [38] reported that, in AD, 5-HT and 5-HIAA
production was speciﬁcally localized in the raphe nucleus.
A decrease in THO transport to axon terminals resulted in
increased concentrations of these molecules, as well as a 4.7-
fold increase in THO activity. High 5-HIAA levels have been
measured in the delirious phase of AD [39].
A major ﬁnding in this work is that all the circulating
antibodies detected were of the IgA isotype, associated with
mucosal immunity, stimulated by exogenous factors (e.g.,
bacteria constituents). Along those lines, Malaguarnera et
al. [40] demonstrated a correlation between the levels of
circulating antibodies directed against Helicobacter pylori
antigens and AD scores. Many authors have suggested that
bacteria play a role in the etiology of AD [41]. Miklossy et
al. demonstrated in vitro that exposing neuronal and glial
cells to Borrelia spirochetes induced morphological changes
related to amyloid deposition, similar to those observed in
AD [42]. Moreover, IDO-1 is induced by many interleukins
and gram-bacteria lipopolysaccharides [43]. IDO-1 is con-
sidered an immunomodulator, as tryptophan “starvation”
prevents bacterial multiplication [44]. Moreover, the over-
production of IDO-1 pathway metabolites is linked to many
cell processes associated with inﬂammation and apoptosis
[45]. Further investigations should thus focus on IDO-1
and THO derivatives linked to endogenous proteins and/or
bacteria components.
4. Conclusion
Circulating antibodies, exclusively of the IgA isotype,
directed against tryptophan metabolites were found in AD
patient sera, thus demonstrating that neurotoxic tryptophan
metabolites are involved in this neurodegenerative disease.
Activation of the IDO-1 pathway leads to overexpression
of these tryptophan metabolites. The production of IgA
antibodies suggests the activation of the mucosal immune
system, possibly by bacterial components. The sequence
of events may start when circulating bacteria components
induce IDO-1 activity. The identiﬁcation of circulating anti-
bodies directed against IDO-1/THO pathway metabolites
contributes to elucidating the etiology of AD.
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